Amgen Archives

News and Trends 8 Sep 2015

The First Biosimilar reached the US market… and it’s from Novartis

Biosimilar or copies of biological drugs are arriving on the market. After Europe, US gets its first Biosimilar too. The drug is produced by Novartis generic subsidiary, Sandoz and it will compete with Amgen‘s blockbuster drug Neupogen. When a drug generates $1.2Bn of annual revenues and its patent has expired, which company on earth wouldn’t be […]

September 8, 2015 - 2 minutesmins - By Philip Hemme

News and Trends 27 Jul 2015

Hunt for Hypercholesterolemia Drug Approval: Sanofi vs Amgen vs Pfizer

Cardiovascular diseases kill around 2.6 million people each year and embody one of the biggest healthcare markets in the World. Not surprising to see Big Pharmas/Biotechs overactive in this field. What are their plans? Today, Sanofi‘s hypercholesterolemia therapy Praluent was recommended to the European market. It is a fully human monoclonal antibody developed in collaboration with the American Big Biotech Regeneron. But Amgen announced […]

July 27, 2015 - 2 minutesmins - By Philip Hemme

News and Trends 26 Mar 2015

The Genomic Portrait of Iceland

A package of four landmark papers were published yesterday in the online edition of Nature Genetics. The research, written by a team of deCODE scientists, was built on whole-genome sequence data from more than 100,000 people from across Iceland. The four milestone studies together present the most detailed portrait of a population yet assembled using the latest technology […]

March 26, 2015 - 4 minutesmins - By Lourdes Riquelme

News and Trends 11 Nov 2014

Ziarco Pharma raises €27M two years after founding

Ziarco Group Ltd, a British biopharmaceutical start-up focusing on inflammatory skin diseases, bags €27M for Series B financing round. This fast-growing 2 year old company already raised €21.4M in a Serie A lead by Pfizer and is now accelerating even more. This second fundraising will enable clinical Phase II Proof-of-Concept studies for ZPL-389, a histamine H4 receptor antagonist […]

November 11, 2014 - 2 minutesmins - By Julie Lellouche

Resources

Categories

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

Approaches

Therapeutic areas

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us